Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer

Noguchi, Masanori; Kojima, Hiroshi; Ishibashi, Midori; Noda, Shinshi

doi:10.1038/sj.bjc.6600715

Cited by 82 publications

(57 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rigaud et al [19] showed in a series of 86 patients with prostate cancer metastases that metastases involving the axial skeleton carry a better prognosis than lesions in appendicular sites. It has also been demonstrated that percentage of positive area for metastases on a bone scan independently predicts survival in metastatic prostate cancer [20] .…”

Section: Discussionmentioning

confidence: 99%

Serum Amino-Terminal Propeptide of Type 1 Procollagen (P1NP) in Prostate Cancer: A Potential Predictor of Bone Metastases and Prognosticator for Disease Progression and Survival

Thurairaja

Iles²,

Jefferson³

et al. 2006

Urol Int

View full text Add to dashboard Cite

Introduction: To determine if amino-terminal propeptide of type 1 procollagen (P1NP) is reliable as a predictor of prostate cancer bone metastases and assess its value as a prognostic indicator of disease progression and survival. Materials and Methods: A cohort of patients with prostate cancer between January 1999 and July 2001 were recruited. Prostate-specific antigen (PSA) and P1NP levels were measured. Two years following completion of recruitment, patient notes were reviewed for symptoms of bone metastases and survival. Results: 24 negative and 12 equivocal or positive bone scans were reported for 36 recruited patients. Mean PSA values for patients with negative, equivocal and positive scans were 18.3, 24.9 and 122.5 ng/ml while mean P1NP for the same groups were 38.2, 73.4 and 119.9 ng/ml. For patients with equivocal and positive scan, mean P1NP with and without bone symptoms were 111.5 and 65.7 ng/ml while for surviving and dead patients the values were 63.9 and 120.8 ng/ml, respectively. Conclusions: Though this study involved a small number of patients, it demonstrates P1NP’s potential as a predictor of bone metastases and a prognosticator for disease progression and survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Amino-Terminal Propeptide of Type 1 Procollagen (P1NP) in Prostate Cancer: A Potential Predictor of Bone Metastases and Prognosticator for Disease Progression and Survival

Thurairaja

Iles²,

Jefferson³

et al. 2006

Urol Int

View full text Add to dashboard Cite

show abstract

“…Oefelein et al [12] reported that skeletal fractures are correlated with decreased overall survival in patients receiving long-term ADT for prostate cancer. Moreover, Noguchi et al [14] found a significant inverse correlation between the percentage of the skeleton affected by metastatic prostate cancer (detected by bone scintigraphy) and survival in a large-scale retrospective analysis. Bone metastases can perturb bone metabolism, as indicated by changes in biochemical markers of bone metabolism (osteolysis and osteogenesis) [15].…”

Section: Importance Of Skeletal Health and Rationale For Bisphosphonamentioning

confidence: 97%

The role of bisphosphonates in the management of prostate cancer

Saad

2006

Curr Oncol Rep

View full text Add to dashboard Cite

Current therapies have extended the survival of patients with prostate cancer. However, these patients often develop skeletal morbidity from disease- and treatment-related effects that undermine skeletal integrity throughout the course of the disease. Low bone mineral density (BMD) is prevalent in patients with early-stage prostate cancer, and androgen-deprivation therapy by either pharmaceutical agent (including hormonal) or surgical castration causes significant decreases in BMD. Fractures can result in a loss of independence and have been associated with shorter survival in patients with prostate cancer. Zoledronic acid is the only bisphosphonate that has demonstrated objective and long-term benefits in reducing skeletal morbidity in patients with bone metastases due to prostate cancer, and it has produced long-term reductions in pain levels compared with placebo in this setting. Therefore, bisphosphonates, particularly zoledronic acid, may provide important benefits for preserving bone health during the course of prostate cancer progression.

show abstract

“…Other proposals include an automated assessment of the percentage of involvement by metastatic bone disease on bone scintigraphy to monitor response to therapy. Although scoring systems of this type may relate to prognosis and response to therapy, they can be time consuming and variable (Sabbatini et al, 1999;Noguchi et al, 2003). Other limiting factors are the lack of anatomical detail.…”

Section: Bone Scintigraphy In Assessment Of Bone Metastasesmentioning

confidence: 99%

Imaging metastatic bone disease from carcinoma of the prostate

2009

View full text Add to dashboard Cite

Imaging bone metastases from prostate cancer presents several challenges. The lesions are usually sclerotic and appear late on the conventional X-ray. Bone scintigraphy is the mainstay of lesion detection, but is often not suitable for assessment of treatment response, particularly because of a 'flare' phenomenon after therapy. Magnetic resonance imaging is increasingly used in assessment, and newer techniques allow quantitation. In addition to 18 F-fluorodeoxyglucose ( 18 FDG), newer PET isotopes are also showing promise in lesion detection and response assessment. This article reviews the available imaging modalities for evaluating prostatic bony metastases, and links them to the underlying pathological changes within bone lesions. British Journal of Cancer (2009) Prostate cancer is the second most common cancer in men, accounting for 1 in 9 of all new cancers, and with more than 670 000 new diagnoses annually worldwide. The metastatic spread is primarily in the skeleton (supporting the 'seed-and-soil' hypothesis described by Paget in 1889) in which lesions are often located in vertebra and ribs because of dissemination through Batson's venous plexus. The spread in bone also follows the distribution of adult red bone marrow, that is, skull, thorax, pelvis, spine, proximal long bones (Imbriaco et al, 1998;Scher, 2003), subsequently progressing to involve adjacent cortical bone. Preclinical models confirm that skeletal sites rich in cellular marrow with active turnover show increased cancer localisation (Schneider et al, 2005). Although predominantly osteoblastic, osteoclast activation also has an important role in the growth of sclerotic metastases in the bone. In a study of 68 men with prostatic bone metastases who underwent surgery for stabilisation of pathological fracture or impending fracture, most metastases were osteoblastic, but 29.1% had metastases that were osteolytic or mixed (Cheville et al,

show abstract

Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer

Cited by 82 publications

References 14 publications

Serum Amino-Terminal Propeptide of Type 1 Procollagen (P1NP) in Prostate Cancer: A Potential Predictor of Bone Metastases and Prognosticator for Disease Progression and Survival

Serum Amino-Terminal Propeptide of Type 1 Procollagen (P1NP) in Prostate Cancer: A Potential Predictor of Bone Metastases and Prognosticator for Disease Progression and Survival

The role of bisphosphonates in the management of prostate cancer

Imaging metastatic bone disease from carcinoma of the prostate

Contact Info

Product

Resources

About